Reproductive Health Clinical Guidance
SMFM and trusted partners provide evidence-based clinical publications to guide reproductive healthcare, including contraception and abortion care. Use the resources below to support best practices in your clinical setting.
- Management of previable and periviable preterm prelabor rupture of membranes ( SMFM Consult Series #71, 2024)
- U.S. Medical Eligibility Criteria for Contraceptive Use (CDC MMWR, SMFM endorsed, 2024)
- U.S. Selected Practice Recommendations for Contraceptive Use (CDC MMWR, SMFM endorsed, 2024)
- Management of hemorrhage at the time of abortion (Joint publication with SFP, 2024)
- Induction of fetal asystole before abortion (Joint publication with SFP, 2024)
- Medication abortion between 14 0/7 and 27 6/7 weeks of gestation (Joint publication with SFP, 2023)
- Cesarean scar ectopic pregnancy (SMFM Consult Series #63, 2022)
- Self-managed abortion (SFP Interim Clinical Recommendations, SMFM endorsed, 2022)
- Care Levels for Fetal Therapy Centers (Consensus Statement, SMFM endorsed, 2022)
- The use of analgesia and anesthesia for maternal-fetal procedures (SMFM Consult Series #59, 2021)
- Counseling women at increased risk of maternal morbidity and mortality (SMFM Consult Series #55, 2021)
- Assessing the risk of maternal morbidity and mortality (SMFM Consult Series #54, 2021)
- Immediate postpartum long-acting reversible contraception (SMFM Consult Series #48, 2019)
- Perinatal Palliative Care (ACOG Committee Opinion #786, SMFM endorsed, 2019)
- Interpregnancy Care (ACOG SMFM Obstetric Care Consensus #8, reaffirmed 2025)
- Periviable Birth (ACOG SMFM Obstetric Care Consensus #6, 2017, reaffirmed 2025)
- Multifetal Pregnancy Reduction (ACOG Committee Opinion #719, SMFM endorsed 2013, reaffirmed 2020)
- Second Trimester Abortion (ACOG Practice Bulletin #135, SMFM endorsed, 2013)
- Consensus report on the detailed fetal anatomic ultrasound examination: indications, components, and qualifications (SMFM endorsed, 2025)
- Access to abortion care (SMFM Position Statement, 2024)
- RhD immune globulin after spontaneous or induced abortion less than 12 weeks of gestation (SMFM Statement, 2024)
- A critical examination of abortion terminology as it relates to access and quality of care (SMFM Special Statement, 2023)
- Clinical considerations for management of severe complications when abortion care is restricted (SMFM Statement, 2022)
- Maternal-fetal medicine subspecialist survey on abortion training and service provision (SMFM Special Statement, 2021)
- Reproductive services for people at high risk for maternal mortality: A report of the workshop (SMFM Report, 2020)
- Reproductive Services for People at High Risk for Maternal Mortality Workshop (SMFM Executive Summary, 2019)
- Increased Risk of Maternal Morbidity Associated With Previable and Periviable Preterm Prelabor Rupture of Membranes (ACOG Practice Advisory, 2025)
- Prevention of infection after abortion and pregnancy loss (SFP Clinical Recommendation, 2025)
- Increasing Access to Abortion (ACOG Committee Statement #16, 2025)
- Self-Managed Abortion (ACOG Committee Statement #13, 2024)
- Medication management for early pregnancy loss (SFP Clinical Recommendation, 2024)
- Medication Abortion up to 70 Days of Gestation (ACOG Practice Bulletin #225, 2020)
- Management of individuals with bleeding or thrombotic disorders undergoing abortion (SFP Clinical Recommendation, 2021)
- Pain control in surgical abortion part 1 - Local anesthesia and minimal sedation (SFP Clinical Recommendation, 2018, reaffirmed 2022)
- Pain control in surgical abortion part 2 – Moderate sedation, deep sedation, and general anesthesia (SFP Clinical Recommendation, 2021)
- Early Pregnancy Loss (ACOG Practice Bulletin #200, 2018, reaffirmed 2025)
- Abortion Training and Education (ACOG Committee Opinion #612, 2014, reaffirmed 2025)
- Induced Abortion and Breast Cancer Risk (ACOG Committee Opinion #434, 2009, reaffirmed 2025)
- The Limits of Conscientious Refusal in Reproductive Medicine (ACOG Committee Opinion #385, 2007, reaffirmed 2019)
- Contraceptive considerations for individuals with cancer and cancer survivors (SFP Clinical Recommendation, 2025)
- Management of undesired pregnancy of unknown location and abortion at less than 42 days of gestation (SFP Clinical Recommendation, 2025)
- Permanent Contraception: Ethical Issues and Considerations (ACOG Committee Statement #8, 2024)
- Contraception and body weight (SFP Committee Statement, 2024)
- Improving Access to Intrauterine Devices and Contraceptive Implants (ACOG Committee Statement #5, 2023)
- Emergency Contraception (SFP Clinical Recommendation, 2023)
- Patient-Centered Contraceptive Counseling (ACOG Committee Statement #1, 2022)
- Extended use of long-acting reversible contraception (SFP Clinical Recommendation, 2022)
- Access to Contraception (ACOG Committee Opinion #615, 2015, reaffirmed 2022)
- Self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (SFP Committee Consensus, 2022)
- Access to Postpartum Sterilization (ACOG Committee Opinion #827,2021, reaffirmed 2024)
- Access to Postabortion Contraception (ACOG Committee Opinion #833, 2021, reaffirmed 2024)
- IUD nomenclature (SFP Committee Statement, 2021)
- Contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth (SFP Clinical Recommendation, 2020)
- Benefits and Risks of Sterilization (ACOG Practice Bulletin #208, 2019)
- Over-the-Counter Access to Hormonal Contraception (ACOG Committee Opinion #788, 2019, reaffirmed 2025)
- Access to Emergency Contraception (ACOG Committee Opinion #707, 2017, reaffirmed 2024)
- Long-Acting Reversible Contraception Implants and Intrauterine Devices (ACOG Practice Bulletin #186, 2017, reaffirmed 2024)
- Clinical Challenges of Long-Acting Reversible Contraceptive Methods (ACOG Committee Opinion #672, 2016, reaffirmed 2024)
- Emergency Contraception (ACOG Practice Bulletin #152, 2015, reaffirmed 2022)
- Depot Medroxyprogesterone Acetate and Bone Effects (ACOG Committee Opinion #602, 2014, reaffirmed 2023)
- Placenta accreta spectrum in the second trimester: A clinical conundrum in procedural abortion care (AJOG, 2025)
- Rh testing in early pregnancy (SFP Committee Consensus, 2022)
- Contraception and abortion care for persons who use substances (SFP Clinical Recommendation, 2022)
- Prevention of RhD Alloimmunization (ACOG Practice Bulletin #181, 2017)
- Gestational Development and Capacity for Pain (ACOG)
These resource compilations are reviewed annually and should not be considered inclusive of all possible relevant resources. Inclusion does not indicate SMFM endorsement unless specifically noted. Questions? Contact the Reproductive Health Team with any questions or suggested additions.